Protocol No. MSDC-0602K-C009NASH: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients with NASH (EMMINENCE™)

  • Rinella, Mary Eugenia (PD/PI)

Project: Research project

Project Details

Effective start/end date12/18/1712/18/20


  • Chiltern International, Inc. (MSDC-0602K-C009NASH // MSDC-0602K-C009NASH)
  • Cirius Therapeutics, Inc. (MSDC-0602K-C009NASH // MSDC-0602K-C009NASH)